Cargando…
Ocular Behçet Disease—Clinical Manifestations, Treatments and Outcomes According to Age at Disease Onset
Behçet disease (BD) is a multisystemic disease that commonly involves the eyes. Although it affects patients in all age groups, data on ocular disease by age of onset are limited. This retrospective, multicenter study aimed to compare epidemiology, systemic and ocular manifestations, treatments and...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9952940/ https://www.ncbi.nlm.nih.gov/pubmed/36831160 http://dx.doi.org/10.3390/biomedicines11020624 |
_version_ | 1784893754132398080 |
---|---|
author | Ostrovsky, Michael Rosenblatt, Amir Iriqat, Salam Shteiwi, Abdallah Sharon, Yael Kramer, Michal Vishnevskia-Dai, Vicktoria Sar, Shaul Boulos, Yosif Tomkins-Netzer, Oren Lavee, Natalie Ben-Arie-Weintrob, Yael Pizem, Hadas Hareuveni-Blum, Tamar Schneck, Marina Gepstein, Raz Masarwa, Dua Nakhoul, Nakhoul Bakshi, Erez Shulman, Shiri Goldstein, Michaella Ramon, Dan Anouk, Marina Habot-Wilner, Zohar |
author_facet | Ostrovsky, Michael Rosenblatt, Amir Iriqat, Salam Shteiwi, Abdallah Sharon, Yael Kramer, Michal Vishnevskia-Dai, Vicktoria Sar, Shaul Boulos, Yosif Tomkins-Netzer, Oren Lavee, Natalie Ben-Arie-Weintrob, Yael Pizem, Hadas Hareuveni-Blum, Tamar Schneck, Marina Gepstein, Raz Masarwa, Dua Nakhoul, Nakhoul Bakshi, Erez Shulman, Shiri Goldstein, Michaella Ramon, Dan Anouk, Marina Habot-Wilner, Zohar |
author_sort | Ostrovsky, Michael |
collection | PubMed |
description | Behçet disease (BD) is a multisystemic disease that commonly involves the eyes. Although it affects patients in all age groups, data on ocular disease by age of onset are limited. This retrospective, multicenter study aimed to compare epidemiology, systemic and ocular manifestations, treatments and outcomes between three age groups: juvenile (<18 years), adult (18–39 years) and late (≥40 years) disease onset. The study included 175 ocular BD patients (303 eyes) from Israel and Palestine: juvenile-onset (n = 25, 14.3%), adult-onset (n = 120, 68.6%) and late-onset (n = 30, 17.1%). Most patients in all groups were male. Systemic manifestations were similar in all groups. Systemic co-morbidities were more common in late-onset patients. Bilateral panuveitis was the most common ocular manifestation in all patients. Non-occlusive retinal vasculitis, peripheral vessel occlusions, cataract and elevated intraocular pressure were found more commonly among juvenile-onset eyes. Anterior uveitis and macular ischemia were most common among late-onset eyes, while branch retinal vein occlusion was most common in adult and late-onset eyes. All patients were treated with corticosteroids. Methotrexate, immunomodulatory combinations and biologic treatments were more commonly used for juvenile-onset patients. All groups had a similar visual outcome. Our study showed that patients with ocular BD have varied ocular manifestations and require different treatments according to age of disease onset, but visual outcome is similar. |
format | Online Article Text |
id | pubmed-9952940 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99529402023-02-25 Ocular Behçet Disease—Clinical Manifestations, Treatments and Outcomes According to Age at Disease Onset Ostrovsky, Michael Rosenblatt, Amir Iriqat, Salam Shteiwi, Abdallah Sharon, Yael Kramer, Michal Vishnevskia-Dai, Vicktoria Sar, Shaul Boulos, Yosif Tomkins-Netzer, Oren Lavee, Natalie Ben-Arie-Weintrob, Yael Pizem, Hadas Hareuveni-Blum, Tamar Schneck, Marina Gepstein, Raz Masarwa, Dua Nakhoul, Nakhoul Bakshi, Erez Shulman, Shiri Goldstein, Michaella Ramon, Dan Anouk, Marina Habot-Wilner, Zohar Biomedicines Article Behçet disease (BD) is a multisystemic disease that commonly involves the eyes. Although it affects patients in all age groups, data on ocular disease by age of onset are limited. This retrospective, multicenter study aimed to compare epidemiology, systemic and ocular manifestations, treatments and outcomes between three age groups: juvenile (<18 years), adult (18–39 years) and late (≥40 years) disease onset. The study included 175 ocular BD patients (303 eyes) from Israel and Palestine: juvenile-onset (n = 25, 14.3%), adult-onset (n = 120, 68.6%) and late-onset (n = 30, 17.1%). Most patients in all groups were male. Systemic manifestations were similar in all groups. Systemic co-morbidities were more common in late-onset patients. Bilateral panuveitis was the most common ocular manifestation in all patients. Non-occlusive retinal vasculitis, peripheral vessel occlusions, cataract and elevated intraocular pressure were found more commonly among juvenile-onset eyes. Anterior uveitis and macular ischemia were most common among late-onset eyes, while branch retinal vein occlusion was most common in adult and late-onset eyes. All patients were treated with corticosteroids. Methotrexate, immunomodulatory combinations and biologic treatments were more commonly used for juvenile-onset patients. All groups had a similar visual outcome. Our study showed that patients with ocular BD have varied ocular manifestations and require different treatments according to age of disease onset, but visual outcome is similar. MDPI 2023-02-19 /pmc/articles/PMC9952940/ /pubmed/36831160 http://dx.doi.org/10.3390/biomedicines11020624 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ostrovsky, Michael Rosenblatt, Amir Iriqat, Salam Shteiwi, Abdallah Sharon, Yael Kramer, Michal Vishnevskia-Dai, Vicktoria Sar, Shaul Boulos, Yosif Tomkins-Netzer, Oren Lavee, Natalie Ben-Arie-Weintrob, Yael Pizem, Hadas Hareuveni-Blum, Tamar Schneck, Marina Gepstein, Raz Masarwa, Dua Nakhoul, Nakhoul Bakshi, Erez Shulman, Shiri Goldstein, Michaella Ramon, Dan Anouk, Marina Habot-Wilner, Zohar Ocular Behçet Disease—Clinical Manifestations, Treatments and Outcomes According to Age at Disease Onset |
title | Ocular Behçet Disease—Clinical Manifestations, Treatments and Outcomes According to Age at Disease Onset |
title_full | Ocular Behçet Disease—Clinical Manifestations, Treatments and Outcomes According to Age at Disease Onset |
title_fullStr | Ocular Behçet Disease—Clinical Manifestations, Treatments and Outcomes According to Age at Disease Onset |
title_full_unstemmed | Ocular Behçet Disease—Clinical Manifestations, Treatments and Outcomes According to Age at Disease Onset |
title_short | Ocular Behçet Disease—Clinical Manifestations, Treatments and Outcomes According to Age at Disease Onset |
title_sort | ocular behçet disease—clinical manifestations, treatments and outcomes according to age at disease onset |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9952940/ https://www.ncbi.nlm.nih.gov/pubmed/36831160 http://dx.doi.org/10.3390/biomedicines11020624 |
work_keys_str_mv | AT ostrovskymichael ocularbehcetdiseaseclinicalmanifestationstreatmentsandoutcomesaccordingtoageatdiseaseonset AT rosenblattamir ocularbehcetdiseaseclinicalmanifestationstreatmentsandoutcomesaccordingtoageatdiseaseonset AT iriqatsalam ocularbehcetdiseaseclinicalmanifestationstreatmentsandoutcomesaccordingtoageatdiseaseonset AT shteiwiabdallah ocularbehcetdiseaseclinicalmanifestationstreatmentsandoutcomesaccordingtoageatdiseaseonset AT sharonyael ocularbehcetdiseaseclinicalmanifestationstreatmentsandoutcomesaccordingtoageatdiseaseonset AT kramermichal ocularbehcetdiseaseclinicalmanifestationstreatmentsandoutcomesaccordingtoageatdiseaseonset AT vishnevskiadaivicktoria ocularbehcetdiseaseclinicalmanifestationstreatmentsandoutcomesaccordingtoageatdiseaseonset AT sarshaul ocularbehcetdiseaseclinicalmanifestationstreatmentsandoutcomesaccordingtoageatdiseaseonset AT boulosyosif ocularbehcetdiseaseclinicalmanifestationstreatmentsandoutcomesaccordingtoageatdiseaseonset AT tomkinsnetzeroren ocularbehcetdiseaseclinicalmanifestationstreatmentsandoutcomesaccordingtoageatdiseaseonset AT laveenatalie ocularbehcetdiseaseclinicalmanifestationstreatmentsandoutcomesaccordingtoageatdiseaseonset AT benarieweintrobyael ocularbehcetdiseaseclinicalmanifestationstreatmentsandoutcomesaccordingtoageatdiseaseonset AT pizemhadas ocularbehcetdiseaseclinicalmanifestationstreatmentsandoutcomesaccordingtoageatdiseaseonset AT hareuveniblumtamar ocularbehcetdiseaseclinicalmanifestationstreatmentsandoutcomesaccordingtoageatdiseaseonset AT schneckmarina ocularbehcetdiseaseclinicalmanifestationstreatmentsandoutcomesaccordingtoageatdiseaseonset AT gepsteinraz ocularbehcetdiseaseclinicalmanifestationstreatmentsandoutcomesaccordingtoageatdiseaseonset AT masarwadua ocularbehcetdiseaseclinicalmanifestationstreatmentsandoutcomesaccordingtoageatdiseaseonset AT nakhoulnakhoul ocularbehcetdiseaseclinicalmanifestationstreatmentsandoutcomesaccordingtoageatdiseaseonset AT bakshierez ocularbehcetdiseaseclinicalmanifestationstreatmentsandoutcomesaccordingtoageatdiseaseonset AT shulmanshiri ocularbehcetdiseaseclinicalmanifestationstreatmentsandoutcomesaccordingtoageatdiseaseonset AT goldsteinmichaella ocularbehcetdiseaseclinicalmanifestationstreatmentsandoutcomesaccordingtoageatdiseaseonset AT ramondan ocularbehcetdiseaseclinicalmanifestationstreatmentsandoutcomesaccordingtoageatdiseaseonset AT anoukmarina ocularbehcetdiseaseclinicalmanifestationstreatmentsandoutcomesaccordingtoageatdiseaseonset AT habotwilnerzohar ocularbehcetdiseaseclinicalmanifestationstreatmentsandoutcomesaccordingtoageatdiseaseonset |